The Global Shift Away From Smoking Is Accelerating: Why the Next Generation of Nicotine Free Solutions Matters

March 13, 2026

Around the world, governments, researchers, and healthcare systems are intensifying efforts to reduce smoking and nicotine addiction. Tobacco remains one of the largest preventable health risks in modern society, and despite decades of public health campaigns, nicotine dependency continues to affect hundreds of millions of people worldwide. At the same time, a major transition is underway. Traditional cigarette use is declining in many developed markets, vaping has emerged as a new category of nicotine consumption, and regulators are increasingly focused on helping people quit nicotine entirely.

For investors and industry observers, this transition represents one of the most significant consumer health shifts of the next decade. The global nicotine economy is changing rapidly, and the companies that provide effective solutions to help smokers break nicotine dependence may be positioned at the center of a massive long term market opportunity.

The scale of the smoking problem remains substantial.

The U.S. Centers for Disease Control and Prevention states that “Cigarette smoking remains the leading cause of preventable disease and death in the United States.” Source https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html

The CDC also reports that cigarette smoking “kills more than 480,000 Americans each year.” Source https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html

Globally, the numbers are even larger. According to the World Health Organization, tobacco use causes more than 8 million deaths every year worldwide. Source https://www.who.int/news-room/fact-sheets/detail/tobacco

Despite decades of public health campaigns, more than 1 billion people worldwide continue to smoke cigarettes.

These numbers illustrate the magnitude of the challenge facing governments, healthcare systems, and regulators. Tobacco addiction is not simply a consumer behavior issue. It is a deeply entrenched public health challenge that affects healthcare costs, workplace productivity, and long term disease outcomes across virtually every country in the world.

At the same time that cigarette smoking remains widespread, the nicotine marketplace itself is evolving.

Over the past decade, electronic cigarettes and vaping devices have grown rapidly as an alternative nicotine delivery system. Vaping products have been marketed by many companies as an alternative to combustible tobacco, but regulators and health authorities continue to evaluate their long term impact.

The Centers for Disease Control explains that “Most e-cigarettes contain nicotine,” and further states that “Nicotine is highly addictive.” Source https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html

Another major concern for regulators has been youth exposure to nicotine products.

According to the CDC, “E-cigarettes are the most commonly used tobacco product among U.S. youth.” Source https://www.cdc.gov/tobacco/e-cigarettes/youth.html

Globally, youth vaping has become a major area of focus for public health organizations. A report cited by Reuters based on World Health Organization data states that “At least 15 million children aged 13 to 15 are estimated to use e-cigarettes globally.” Source https://www.reuters.com/business/healthcare-pharmaceuticals/who-estimates-least-15-million-teenagers-use-e-cigarettes-worldwide-2025-10-06/

Researchers have also studied the composition of vapor from electronic cigarettes. According to the CDC, “E-cigarette aerosol can contain harmful substances, including nicotine, cancer-causing chemicals, heavy metals such as nickel, tin, and lead, volatile organic compounds, and ultrafine particles that can be inhaled deep into the lungs.” Source https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html

Public health researchers have also examined how vaping may influence long term smoking behavior. One large review of research found that young people who vape are “three times as likely to start smoking.” Source https://www.theguardian.com/society/2025/aug/19/young-vape-users-three-times-as-likely-to-start-smoking-study

Taken together, these developments illustrate the complexity of the modern nicotine marketplace. While traditional cigarette use has declined in some regions, nicotine addiction remains widespread. At the same time, the emergence of new nicotine delivery systems has created additional challenges for regulators and healthcare systems.

Market Opportunity

The size of the smoking cessation market highlights why innovation in this space has drawn increasing attention from investors and healthcare leaders. With more than 1 billion smokers worldwide and growing regulatory pressure on both cigarettes and vaping products, governments and healthcare systems are actively searching for more effective cessation solutions.

The global smoking cessation market already represents a multibillion dollar industry and continues to grow as countries implement stronger tobacco control policies. Public health campaigns, insurance programs, and healthcare providers increasingly encourage smokers to quit. Yet relapse rates remain high, and many smokers struggle to break nicotine dependence even when using traditional cessation tools.

Even small improvements in cessation success rates could represent enormous economic and healthcare benefits. For this reason, technologies that help smokers transition away from nicotine entirely are attracting growing attention across the healthcare and investment communities.

Why Redwood Is Positioned for This Market

Redwood Scientific Technologies is focused on developing nicotine free technologies designed to support smoking and vaping cessation. Through its TBX FREE and TBX VAPE FREE platforms, the company is developing oral thin film solutions intended to address behavioral patterns associated with smoking without introducing nicotine.

Unlike many nicotine replacement products that continue to deliver nicotine to the user, Redwood’s technology focuses on nicotine free approaches intended to help smokers transition away from both combustible cigarettes and nicotine based alternatives.

This approach aligns with a growing interest among regulators, healthcare providers, and consumers in solutions that eliminate nicotine dependence rather than simply replacing one nicotine delivery system with another.

As regulatory pressure increases and public awareness continues to grow, technologies designed to help smokers transition away from nicotine entirely may play an increasingly important role in the global health landscape.

The global shift away from smoking is already underway.

For investors, policymakers, and healthcare leaders, the question is no longer whether this transition will occur. The question is which technologies and companies will lead the next generation of solutions.

In a market measured in hundreds of billions of dollars and driven by one of the most persistent public health challenges in the world, the potential impact is enormous.

About Redwood Scientific Technologies, Inc.

Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.

Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.

Additional information about Redwood Scientific Technologies can be found at

https://redwoodsci.com

Additional Company Disclosure

Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.

Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.

Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.

In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.

Forward Looking Statement Notice

Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.

Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.

This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.

Back to blog